Marksans Pharma Ltd Q1 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/6szmkr2astqw3lcx8mvp7rpx.pdf

Key Takeaways


U.K. Market: Price Erosion and Portfolio Shift

Mark Saldanha: "The historic products of Rx will definitely be more volatile, and the newer molecules will be much more profitable. So, I guess we have to just stay one step ahead of the curve."

U.S. Market: Tariff Overhang and Contract Stability

Mark Saldanha: "But today, it does not make sense for us to panic because literally, I don't think anyone knows what's going to happen tomorrow."

Margins: One-Off Hits and Sequential Recovery


Order Book and Revenue Trajectory


Strategic Expansion and Capacity

Mark Saldanha: "So, these uncertainties are the ones that are most unpredictable and difficult to answer. And I guess the market is -- I mean, we don't have a crystal ball."

Guidance & Commitments

CommitmentSpecificsTimeline
U.K. sequential recoveryQ2 "much better" than Q1, Q3 better than Q2, Q4 between Q2 and Q3Through FY26
U.K. full-year revenueFlattishFY26
U.S. growthWill grow; contracts are in placeFY26
FY26 revenue"Very close to INR3,000 crores or maybe shy away," still growing over last yearFY26
FY26 EBITDA margin"Somewhere between last year margin and the 17%" (17.8% excluding ECL)FY26
Gross marginsWill continue to be healthyOngoing
Order book execution$45–50 mn of $220 mn order book execution beginsOctober–December 2025
Teva facility revenueAim to reach INR800-odd croresNo date (progressing month-on-month)
U.K. Rx portfolio evolutionPortfolio to become "much more robust and profitable" via complex, niche molecules1 to 1.5 years
Organic Germany entryLaunching organicallyMedium- to long-term (no date)

Key Metrics

MetricQ1 FY26
Operating revenue₹620 cr, +5% YoY vs ₹590.6 cr
U.S. and North America revenue₹327.6 cr, +30.6% YoY
U.K. and EU formulation revenue₹203.8 cr
Australia and New Zealand revenue₹57 cr
Rest of world revenue₹31.6 cr
Gross profit₹358.2 cr, +8.9% YoY
Gross margin57.8%, expanded 209 bps YoY from 55.7%
EBITDA₹100.1 cr
EBITDA margin16.1%, decreased 560 bps YoY
EBITDA margin excluding one-time ECL provision~17.8% (per an analyst's math)
One-time expected credit loss provision₹10.48 cr for emerging market division
Mark-to-market provision on forward contracts₹6.2 cr for GBP exports to U.K.
Order book$220 million
Order book execution starting Oct–Dec 2025$45 million to $50 million
Teva facility revenue run-ratetrending towards ₹500 cr, up from ₹400-odd cr in Q4 FY25
Teva facility revenue potential₹800-odd cr, with 40% additional utilization available
U.K. portfolio split60% OTC, 40% Rx
U.S. portfolio split90% OTC, 10% Rx
U.K. share of total revenue40% to 45%
U.S. manufacturing share of revenue~35% to 40% manufactured in U.S., rest in India
Tariff on raw materials imported from China20%
Regulatory approvals received in Q13 from U.S. FDA and U.K. MHRA
High-margin liquid products launched in U.K.4